Biogen Idee

Rituxan Rituximab IDEC (now Biogen Idee), Gambridge, MA Anti-CD20 Non-Hodgkin s lymphoma 1997... [Pg.580]

ZevaHn Ibritumomab tiuxetan Biogen Idee Radiolabeled anti-CD20 Non-Hodgkin s lymphoma 2002... [Pg.580]

Tysabri Natalizumab Biogen Idee Anti-alpha 4 Multiple sclerosis 2005... [Pg.580]

Mitchell E. Reff Biogen Idee, Inc., Oncology, Cambridge, Massachusetts, U.S. [Pg.666]

Rituxan Non-Hodgkin s lymphoma Biogen Idee, Genentech, Roche... [Pg.7]

Interferon-j81-a Avonex, Rebif Biogen Idee, Serono 2012 2008 and 2013... [Pg.354]

Computational Drug Design Groups Department of Research Informatics Biogen Idee 12 Cambridge Center Cambridge, MA 02142 USA... [Pg.1]

Biogen Idee Inc. and Genentech Inc. 2005. Rituxan prescribing information. [Pg.326]

Experimental data discussed in this chapter were derived from Biogen Idee sponsored studies. The authors wish to acknowledge the contributions of many scientists in the Research and Development organization at Biogen Idee in the design and execution of these studies. [Pg.204]

Ibritumomab tiuxetan Zevalin Biogen Idee Anti-CD20- Yttrium 90 IgGl kappa Oncology 2002... [Pg.591]

Natal izumab Tysabri Biogen idee Anti-a4-integrin IgG4 Multiple sclerosis 2004... [Pg.593]

David Hutto, PhD, DVM, Senior Director, Comparative Pathology, Biogen Idee, Inc., 14 Cambridge Ctr., Cambridge, MA 02142... [Pg.1099]

Bowes, S. et al. 2006. Quality assessment and analysis of Biogen Idee compound library. J. Biomol. Screen. 11, 828-835 Epub Sept. 6, 2006. [Pg.210]

Shares in Elan and Biogen Idee plunged as the firms suspended sales of new multiple sclerosis drug T sabri after a patient s death (finally 3 died) in the US. ... [Pg.316]

ZEVALIN (Ibritumomab Biogen Idee Liquid 3.2 mg single- 3.2 mg in 2 mL of 0.9% tiuxetan) dose vial NaCl... [Pg.332]

Two drugs initially withdrawn were allowed back by the FDA in U.S. markets. Lotronex (Alosetron, Glaxo Smith Kline) for irritable bowel syndrome was approved in early 2000 and withdrawn 9 months later due to serious gastrointestinal problems. It was reapproved with restrictions in 2002. Tysabri (Natalizumab, Biogen Idee, Elan) for multiple sclerosis was approved in late 2004 and withdrawn in 2005 due to rare fatal brain lesions and was allowed back in mid-2006. [Pg.165]

Rituximab Rituxan Roche, Biogen Idee Leukemia, Lymphoma Rheumatoid Arthritis 2.8 3.2 4.7... [Pg.175]

Human Growth Hormone Serostim, Saizen, Humatrope, Protopin, Neutropin, Genotropin Merck Serono, Biogen Idee, Roche, Novo Nordisk, Akzo Nobel, Lilly, Pfizer Dwarfism 1.8 2.2 2.4... [Pg.175]

Recent R D failures include Biogen Idee, Lilly-ICOS, and Alexion products in clinical trials. The Roche monoclonal antibody to the IL-6 receptor for RA (MRA) has shown efficacy in RA patients not responding to methotrexate and TNF inhibitors. If long-term safety, efficacy, and remission of new biologies are established in osteoarthritis trials, it will be an important therapeutic advance and create a large market. [Pg.182]

Alefacept (Amevive, Biogen Idee) and Efalizumab (Reptiva, Xoma, Genentech, Serono), the two monoclonal antibodies, which block the activation of T cells, were hailed as major advances in the treatment of psoriasis. The sales of Reptiva were 112 million and 160 million and of Amevive were 48 and 15 million in 2005 and 2006 below initial sales forecasts mainly due to competition from TNF inhibitors [45]. The technical success of R D of non TNF biologicals for treatment of psoriasis has not translated into commercial success due to the large clinical data base and dominance of TNF antagonist products. [Pg.182]

Purification of a therapeutic monoclonal antibody Scale-down characterization studies for various filtration and chromatography steps (including viral clearance) to predetermine acceptance criteria [87] (Biogen Idee)... [Pg.354]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...